Skip to main content

Charles River Laboratories ratios

  • CRL · NYSE
  • Biotechnology
  • Life Sciences Tools & Services
  • S&P 500
$337.97−0.83%Close 13 Nov 2026 · Market value $16.04B

In fiscal 2025 (the year to 27 Dec 2025), Charles River Laboratories had an operating margin of 0.6%, a return on equity of −4.4%, a return on invested capital of 0.3%.

From Charles River Laboratories's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 27 Dec 2025.

Annual

Charles River Laboratories ratios, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Gross margin80.5%78.2%77.7%76.5%77.2%76.6%79.5%80.6%83.5%84.4%—36.6%36.7%37.7%36.8%36.4%32.9%33.0%
Operating margin−34.9%14.5%−26.3%15.3%14.7%13.0%13.7%15.1%14.1%15.5%14.6%13.4%14.8%16.7%16.4%14.9%5.6%0.6%
Net margin−40.5%9.8%−29.7%9.6%8.6%8.8%9.8%11.0%9.2%6.6%10.0%9.6%12.5%11.0%12.2%11.5%0.5%−3.6%
Free cash flow margin6.5%12.4%11.1%13.7%14.2%14.4%15.0%17.7%15.6%12.7%13.3%13.0%13.0%15.0%7.4%8.8%12.4%12.9%
Return on equity−42.2%8.7%−32.6%18.1%17.3%16.6%19.3%21.3%19.7%13.1%19.2%17.1%19.4%16.8%17.6%14.4%0.6%−4.4%
Return on assets—5.6%−12.0%9.2%8.3%7.2%7.4%8.2%7.0%4.3%7.9%6.9%6.9%7.8%7.0%6.5%2.3%0.3%
Return on capital employed—8.7%−17.4%12.4%12.8%11.5%12.0%12.4%11.8%12.1%11.5%9.6%10.0%11.1%10.4%9.0%3.3%0.4%
Return on invested capital—6.6%−14.5%11.2%9.8%8.8%9.2%9.9%8.3%5.2%9.4%8.1%8.1%9.1%8.2%7.4%2.6%0.3%
Current ratio—2.382.131.961.422.241.971.791.531.781.611.441.431.231.321.521.411.29
Debt to equity—0.361.021.371.111.031.121.141.451.071.261.241.021.161.060.870.800.83
Net debt / EBITDA—1.20—2.482.232.002.172.323.002.212.963.252.893.173.053.064.395.64
Interest coverage−20.237.82−8.464.094.977.2214.8713.708.579.685.205.775.017.9810.984.521.800.24
Cash conversion−16.0%127%−37.5%143%165%163%153%162%169%191%133%135%104%136%60.7%77.0%2259%−359%
SBC / Revenue1.9%2.0%2.3%1.9%1.9%2.1%2.4%2.9%2.6%2.4%2.1%2.2%1.9%2.0%1.9%1.7%1.7%1.8%

Quarterly

Charles River Laboratories ratios, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Gross margin35.9%34.1%34.5%34.6%28.4%32.3%34.6%33.7%31.1%29.6%36.2%36.4%
Operating margin13.1%12.5%14.8%11.6%−16.7%7.6%9.7%13.3%−28.5%12.0%11.9%20.6%
Net margin18.5%7.2%9.2%6.9%−21.4%2.6%5.1%5.4%−27.8%−1.5%−0.1%33.9%
Free cash flow margin14.1%5.0%15.0%21.1%8.4%11.4%16.4%17.7%5.9%−1.5%14.8%21.1%
Return on equity5.2%2.0%2.5%1.8%−6.2%0.8%1.6%1.6%−8.7%−0.5%−0.1%10.3%
Return on assets1.5%1.2%1.5%1.1%−1.8%0.7%1.0%1.1%−3.1%1.2%1.3%2.1%
Return on capital employed1.9%1.8%2.2%1.7%−2.6%1.1%1.5%2.1%−4.7%1.8%1.9%3.2%
Return on invested capital1.7%1.3%1.7%1.3%−2.0%0.8%1.1%1.3%−3.7%1.4%1.5%2.5%
Current ratio1.521.751.581.481.411.431.361.371.291.361.351.41
Debt to equity0.870.850.760.730.800.930.830.770.831.041.070.88
Net debt / EBITDA13.3413.0211.1912.40—14.1311.8511.06—15.3515.189.64
Interest coverage3.963.604.633.88−5.942.683.345.27−11.924.483.957.10
Cash conversion76.2%69.6%164%306%−39.0%441%324%328%−21.2%99.9%−10028%62.2%
SBC / Revenue1.9%1.7%1.6%1.9%1.7%1.3%1.7%2.3%1.8%2.2%2.0%2.1%

The main figures as JSON and plain text. See data and methodology.

CRL in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.